Nanobiotix Shares Surge 5.23% at Close, Boosted by Target Upgrade
Nanobiotix shares closed up 5.23% on Wednesday, December 10, following a target price raise by Leerink Partners from $24 to $26 on its American listing, maintaining an 'Outperform' rating. The stock has shown significant growth over the past year, with advancements in its clinical pipeline, particularly with its leading candidate NBTXR3 in partnership with Johnson & Johnson.
Significant Daily and Annual Gains
Nanobiotix's stock ended the session on Wednesday, December 10, up 5.23% at 19.30 euros, compared to 18.34 euros the previous day. This increase followed Leerink Partners raising its target price to $26 from $24 on its American listing, while maintaining an 'Outperform' recommendation. Trading volumes reached 1.06% of the capital, indicating a renewed investor interest in this biotechnological stock. Over the past week, the stock has performed remarkably well with a 9.91% increase, confirming the upward trend that has been ongoing for several months. On a quarterly basis, the increase is 144.9%, and over the year, the stock has soared by 524.2%, significantly outperforming the Paris market. This exceptional trajectory is due to continuous advancements in the company's clinical pipeline, particularly in the development of its flagship candidate NBTXR3 in partnership with Johnson & Johnson. The stock now fluctuates between a technical support at 15.52 euros and a resistance at 19.56 euros, the latter being a major psychological threshold approached by the current price.
Strategic Developments and Financial Strength
Leerink Partners cited Nanobiotix's third-quarter 2025 cash balance update and developments in its pipeline as meeting expectations. Nanobiotix is expected to provide several clinical data updates for NBTXR3 in 2026, which reinforces investor interest in this high-potential biotechnological stock. Leerink Partners also noted the transfer of the sponsorship of the Phase III NANORAY-312 study of NBTXR3 in locally advanced squamous cell carcinoma of the head and neck to Johnson & Johnson. Financially, the French biotech recently finalized a non-dilutive financing agreement with HealthCare Royalty that could reach $71 million, extending its cash runway until early 2028. This financial strength allows Nanobiotix to continue developing its pipeline in several oncological indications, including pancreatic, lung, and esophageal cancers. These expected clinical catalysts in 2026 are major milestones that could significantly impact the stock's valuation in the coming months.
Technical Indicators and Market Movements
From a technical perspective, the RSI is positioned at 48, a perfectly neutral level indicating that the stock is neither in an overbought nor oversold zone, leaving room for movement in both directions. The price is slightly above its 50-day moving average established at 18.66 euros, confirming the strength of the medium-term trend. The MACD shows an encouraging configuration with a positive histogram at 0.06, the MACD line at 0.05 is above the signal line at 0.00, signaling potential for continuation of the upward movement in the short term. The Bollinger Bands frame the price between 17.05 euros and 19.25 euros, with the stock operating in the upper part of this channel, indicating sustained buying pressure. Volatility remains measured at 15.54% over a month, a relatively contained level for a biotechnological stock in clinical development phase. The significant gap with the 200-day moving average, which stands at 8.46 euros, materializes the spectacular acceleration of the stock since the beginning of the year. Additionally, Goldman Sachs declared on December 2 that it had crossed below the 5% threshold of Nanobiotix's capital on November 26, a notable shareholder movement following the strong appreciation of the stock.
